[{"id":"da2147db-6d4b-4bfe-ac5e-f6786f79f209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881265","created_at":"2023-05-31T15:05:36.513Z","updated_at":"2025-02-25T14:17:59.340Z","phase":"Phase 2","brief_title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT05881265","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-18"},{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"75b36792-3537-4fd9-bb98-a6b74bb163b9","acronym":"ECOG-ACRIN-EA9131","url":"https://clinicaltrials.gov/study/NCT03253848","created_at":"2021-01-18T16:04:28.074Z","updated_at":"2024-07-02T16:34:26.963Z","phase":"","brief_title":"Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT03253848 - ECOG-ACRIN-EA9131","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" RARA","pipe":"","alterations":" ","tags":["RARA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 09/26/2017","start_date":" 09/26/2017","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 08/18/2025","study_completion_date":" 08/18/2025","last_update_posted":"2024-06-12"},{"id":"5c7bafb8-a49c-4d34-97a5-3ed538c792ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05832320","created_at":"2023-04-27T14:04:55.563Z","updated_at":"2024-07-02T16:35:04.431Z","phase":"","brief_title":"Optimum Induction Therapy of Low-risk APL","source_id_and_acronym":"NCT05832320","lead_sponsor":"Peking University People's Hospital","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"eae87f81-b151-4534-856f-6fe520d9c93c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04793919","created_at":"2024-04-15T17:24:45.119Z","updated_at":"2024-07-02T16:35:09.764Z","phase":"Phase 2","brief_title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT04793919","lead_sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 10/09/2025","primary_completion_date":" 10/09/2025","study_txt":" Completion: 10/10/2027","study_completion_date":" 10/10/2027","last_update_posted":"2024-04-15"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"2aab645e-82e6-4871-a584-636d0a665d5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897490","created_at":"2021-05-21T11:52:52.627Z","updated_at":"2024-07-02T16:35:24.138Z","phase":"","brief_title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","source_id_and_acronym":"NCT04897490","lead_sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","biomarkers":" BCR","pipe":" | ","alterations":" FLT3 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-09"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"f217b7d9-3e47-4a87-b909-a8c4c9782009","acronym":"DaunoDouble","url":"https://clinicaltrials.gov/study/NCT02140242","created_at":"2021-07-17T10:53:01.305Z","updated_at":"2024-07-02T16:35:36.908Z","phase":"Phase 3","brief_title":"Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML","source_id_and_acronym":"NCT02140242 - DaunoDouble","lead_sponsor":"Technische Universität Dresden","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 721","initiation":"Initiation: 04/16/2014","start_date":" 04/16/2014","primary_txt":" Primary completion: 04/25/2022","primary_completion_date":" 04/25/2022","study_txt":" Completion: 04/25/2022","study_completion_date":" 04/25/2022","last_update_posted":"2023-09-15"},{"id":"bd429bf9-43d9-49a2-89cf-f278098b48a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003861","created_at":"2022-04-24T08:53:54.737Z","updated_at":"2024-07-02T16:35:38.510Z","phase":"","brief_title":"Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT00003861","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 840","initiation":"Initiation: 04/01/1999","start_date":" 04/01/1999","primary_txt":" Primary completion: 01/01/2100","primary_completion_date":" 01/01/2100","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-31"},{"id":"ca1e75d4-24cd-4bf5-b1bc-b2590263f177","acronym":"","url":"https://clinicaltrials.gov/study/NCT01756118","created_at":"2021-01-17T17:42:08.990Z","updated_at":"2024-07-02T16:35:55.304Z","phase":"Phase 1","brief_title":"A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia","source_id_and_acronym":"NCT01756118","lead_sponsor":"Goethe University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dactolisib (RTB101) • sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 02/07/2020","study_completion_date":" 02/07/2020","last_update_posted":"2023-02-16"},{"id":"524a0eb6-071e-4968-ae8c-51db52817873","acronym":"","url":"https://clinicaltrials.gov/study/NCT00492856","created_at":"2021-01-18T01:45:43.940Z","updated_at":"2024-07-02T16:35:57.935Z","phase":"Phase 3","brief_title":"S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT00492856","lead_sponsor":"Southwest Oncology Group","biomarkers":" PML","pipe":" | ","alterations":" Chr t(15;17)","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Mylotarg (gemtuzumab ozogamicin) • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 05/04/2016","study_completion_date":" 05/04/2016","last_update_posted":"2023-01-10"},{"id":"a38ba7d6-a220-4bff-9bf0-90309625cd62","acronym":"APL0406","url":"https://clinicaltrials.gov/study/NCT00482833","created_at":"2021-03-29T12:16:38.586Z","updated_at":"2024-07-02T16:36:02.654Z","phase":"Phase 3","brief_title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","source_id_and_acronym":"NCT00482833 - APL0406","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idarubicin hydrochloride • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 276","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 10/17/2019","study_completion_date":" 10/17/2019","last_update_posted":"2022-10-11"},{"id":"20f89bfd-19a7-41d7-824a-1d01ee002b27","acronym":"","url":"https://clinicaltrials.gov/study/NCT01253070","created_at":"2021-01-18T05:03:01.330Z","updated_at":"2024-07-02T16:36:06.069Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01253070","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • RUNX1","pipe":" | ","alterations":" FLT3 mutation • Chr t(15;17)","tags":["FLT3 • RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 10/31/2014","primary_completion_date":" 10/31/2014","study_txt":" Completion: 04/15/2021","study_completion_date":" 04/15/2021","last_update_posted":"2022-08-04"},{"id":"74b84726-5dfa-4905-ad2e-aecfba9ada28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02200978","created_at":"2021-01-18T10:17:32.797Z","updated_at":"2024-07-02T16:36:10.731Z","phase":"Phase 4","brief_title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","source_id_and_acronym":"NCT02200978","lead_sponsor":"South China Children's Leukemia Group","biomarkers":" PML","pipe":" | ","alterations":" RARA positive","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RARA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-05-10"},{"id":"8a7bbd71-8642-4694-a50d-cc6f1326a302","acronym":"","url":"https://clinicaltrials.gov/study/NCT01404949","created_at":"2021-01-18T05:46:30.343Z","updated_at":"2024-07-02T16:36:20.058Z","phase":"Phase 2","brief_title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","source_id_and_acronym":"NCT01404949","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TERT • PML","pipe":"","alterations":" ","tags":["TERT • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-11-30"},{"id":"5b85a06d-98ac-4bb5-a96b-be603b8c9a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT00201240","created_at":"2021-01-18T00:41:05.413Z","updated_at":"2024-07-02T16:36:21.783Z","phase":"Phase 2","brief_title":"Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)","source_id_and_acronym":"NCT00201240","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" HLA-DRB1 • CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 06/01/2005","start_date":" 06/01/2005","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2021-11-01"},{"id":"cd2a2120-8206-4bc7-97e5-99651be9b52b","acronym":"Ara-C","url":"https://clinicaltrials.gov/study/NCT01191541","created_at":"2021-02-21T23:52:19.111Z","updated_at":"2024-07-02T16:36:26.660Z","phase":"Phase 4","brief_title":"Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)","source_id_and_acronym":"NCT01191541 - Ara-C","lead_sponsor":"Xiaofan Zhu","biomarkers":" RARA","pipe":"","alterations":" ","tags":["RARA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2021-08-10"},{"id":"5063235e-ff35-4131-9838-661453788f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445080","created_at":"2021-01-18T05:59:35.791Z","updated_at":"2025-02-25T16:23:43.042Z","phase":"Phase 1/2","brief_title":"Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia","source_id_and_acronym":"NCT01445080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 05/30/2006","start_date":" 05/30/2006","primary_txt":" Primary completion: 03/16/2012","primary_completion_date":" 03/16/2012","study_txt":" Completion: 12/10/2012","study_completion_date":" 12/10/2012","last_update_posted":"2021-02-02"},{"id":"48f43301-76ea-4392-93f8-8bc868a9983f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00105001","created_at":"2021-01-18T00:20:30.652Z","updated_at":"2024-07-02T16:36:54.115Z","phase":"Phase 2","brief_title":"Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00105001","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 210","initiation":"Initiation: 11/01/2004","start_date":" 11/01/2004","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 05/08/2015","study_completion_date":" 05/08/2015","last_update_posted":"2019-10-30"},{"id":"ca1cce76-4da6-4fbf-bdfa-002e28a88250","acronym":"APL2012","url":"https://clinicaltrials.gov/study/NCT01987297","created_at":"2022-05-31T05:55:44.114Z","updated_at":"2024-07-02T16:36:56.825Z","phase":"Phase 4","brief_title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","source_id_and_acronym":"NCT01987297 - APL2012","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • idarubicin hydrochloride • arsenic trioxide"],"overall_status":"Unknown status","enrollment":" Enrollment 738","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2019-08-19"},{"id":"52fed3d4-413e-4097-86f8-0092fe2f7147","acronym":"","url":"https://clinicaltrials.gov/study/NCT00413166","created_at":"2021-01-18T01:27:04.006Z","updated_at":"2024-07-02T16:36:59.866Z","phase":"Phase 2","brief_title":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","source_id_and_acronym":"NCT00413166","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2019-05-07"}]